Table 2 Clinical data
From: Methylation status of TSHr in well-differentiated thyroid cancer by using cytologic material
Group | Age (mean ± SD) | Sex (M:F) | Ultrasonographic diameter of nodule (mean ± SD, mm) | Serum Thyroglobulin [median, mg/dl (IQR)] | Cases with high (>50 mg/dl) thyroglobulin (%) |
|---|---|---|---|---|---|
B | 50 ± 14 | 1:15 | 26 ± 9 | 47.8 (20.0–160.3) | 50 |
PTC | 40 ± 10 | 4:11 | 14 ± 8 | 9.3 (0.2–98.0) | 33 |
AUS | 52 ± 13 | 2:26 | 22 ± 12 | 33.0 (1.3–119.0) | 36 |
AUS-B | 55 ± 13 | 1:14 | 22 ± 13 | 41 (0.3–135.5) | 39 |
AUS-M | 48 ± 13 | 1:12 | 23 ± 11 | 20 (3.1–96.5) | 33 |
FN | 54 ± 14 | 3:7 | 33 ± 11 | 16.7 (3.0–66.3) | 25 |
FN-B | 50 ± 14 | 2:2 | 28 ± 5 | 8.4 (2.6–32.7) | 0 |
FN-M | 57 ± 15 | 1:5 | 36 ± 13 | 35.4 (5.7–159.0) | 50 |